Literature DB >> 25622054

Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant.

Hiroshi Mohri1, Nicole Prada, Martin Markowitz.   

Abstract

Multidrug-resistant (MDR) HIV-1 viruses are thought to be less pathogenic than wild-type viruses because of the fitness costs of drug-resistance mutations. However, we identified an individual infected with MDR virus associated with rapid disease progression referred to as MDR-1. To study the contribution of virologic factors to rapid disease progression, we constructed molecular clones that demonstrated high replication fitness and cytopathicity. To dissect determinants of enhanced fitness of a cytopathic clone, pMDR-1c, we divided its genome into 2 parts: the envelope (gp160) and the remaining backbone genome, and constructed mutual chimeric viruses with a reference, wild-type virus clone, pNL4-3. The growth competition assay indicated that pMDR-1c has high fitness (1.62), although its envelope confers remarkably enhanced fitness (2.29) and its backbone confers reduced fitness (0.56) as compared with pNL4-3. We also performed a similar study with a less cytopathic pMDR-5a, a molecular clone derived from another subject MDR-5, infected with MDR HIV-1, and associated with slower clinical progression. The results indicated that pMDR-5a has reduced fitness (0.82), although its envelope confers enhanced fitness (1.64) and its backbone confers reduced fitness (0.49), a fitness pattern compatible with envelope-mediated fitness compensation. These results suggest that the viral envelope may be a major determinant of the enhanced fitness of the MDR HIV-1 variant isolated from a patient with rapid disease progression. Furthermore, we speculate that compensation conferred by envelope may be a mechanism by which MDR HIV-1 maintains overall fitness despite the presence of changes in pol, which reduce replication capacity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25622054      PMCID: PMC4357569          DOI: 10.1097/QAI.0000000000000524

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  37 in total

1.  Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.

Authors:  Martin Markowitz; Hiroshi Mohri; Saurabh Mehandru; Anita Shet; Leslie Berry; Roopa Kalyanaraman; Alexandria Kim; Chris Chung; Patrick Jean-Pierre; Amir Horowitz; Melissa La Mar; Terri Wrin; Neil Parkin; Michael Poles; Christos Petropoulos; Michael Mullen; Daniel Boden; David D Ho
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

2.  Improved envelope function selected by long-term cultivation of a translation-impaired HIV-1 mutant.

Authors:  A T Das; A P van Dam; B Klaver; B Berkhout
Journal:  Virology       Date:  1998-05-10       Impact factor: 3.616

3.  Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

Authors:  J Martinez-Picado; A V Savara; L Sutton; R T D'Aquila
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

Authors:  Jens Verheyen; Elena Litau; Tobias Sing; Martin Däumer; Melanie Balduin; Mark Oette; Gerd Fätkenheuer; Jürgen K Rockstroh; Ulrike Schuldenzucker; Daniel Hoffmann; Herbert Pfister; Rolf Kaiser
Journal:  Antivir Ther       Date:  2006

5.  Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Authors:  Andre J Marozsan; Dawn M Moore; Michael A Lobritz; Erika Fraundorf; Awet Abraha; Jacqueline D Reeves; Eric J Arts
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Web resources for HIV type 1 genotypic-resistance test interpretation.

Authors:  Tommy F Liu; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

7.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.

Authors:  Ming Zhang; Brian Gaschen; Wendy Blay; Brian Foley; Nancy Haigwood; Carla Kuiken; Bette Korber
Journal:  Glycobiology       Date:  2004-06-02       Impact factor: 4.313

8.  Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.

Authors:  Hulin Wu; Yangxin Huang; Carrie Dykes; Dacheng Liu; Jingming Ma; Alan S Perelson; Lisa M Demeter
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 9.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

10.  The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques.

Authors:  G B Karlsson; M Halloran; D Schenten; J Lee; P Racz; K Tenner-Racz; J Manola; R Gelman; B Etemad-Moghadam; E Desjardins; R Wyatt; N P Gerard; L Marcon; D Margolin; J Fanton; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  1 in total

1.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.